Discounted for Margin and Peer Weakness
Boston Scientific trades at a discount for understandable reasons. Margins and ROIC lag sector leaders, and segment headwinds persist. In medtech, that’s a problem. Only a clear margin recovery and market share gains would shift the market’s view.
Published by AssetNext · 2026-05-28
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-06-11 | Profile and price weak | 55 | -56.4% | -16.2% |
| 2026-06-04 | Profile and price weak | 56 | -54.8% | -19.8% |
| 2026-05-27 | Profile and price weak | 51 | -53.3% | -11.7% |
Break down BSX's structural position across all peer dimensions with the interactive app.